We participated in the Cathepsin S (CatS) sub-challenge of the Drug Design Data Resource (D3R) Grand Challenge 3 (GC3) in 2017 to blindly predict the binding poses of 24 CatS-bound ligands, the binding affinity ranking of 136 ligands, and the binding free energies of a subset of 33 ligands in Stage 1A and Stage 2. Our submitted predictions ranked relatively well compared to the submissions from other participants. Here we present our methodologies used in the challenge. For the binding pose prediction, we employed the Glide module in the Schrodinger Suite 2017 and AutoDock Vina. For the binding affinity/free energy prediction, we carried out molecular dynamics simulations of the complexes in explicit water solvent with counter ions, and then estimated the binding free energies with our newly developed model of extended linear interaction energy (ELIE), which is inspired by two other popular end-point approaches: the linear interaction energy (LIE) method, and the molecular mechanics with Poisson-Boltzmann surface area solvation method (MM/PBSA). Our studies suggest that ELIE is a good trade-off between efficiency and accuracy, and it is appropriate for filling the gap between the high-throughput docking and scoring methods and the rigorous but much more computationally demanding methods like free energy perturbation (FEP) or thermodynamics integration (TI) in computer-aided drug design (CADD) projects.
Introduction
Drug Design Data Resource (D3R) [1] is an NIH founded organization based at the University of California San Diego (UCSD). D3R collects high-quality, unpublished crystal structures and affinity data of protein-ligand binding complexes donated by pharmaceutical companies, and uses these data to organize challenges of blind prediction of ligand binding poses and protein-ligand binding affinities [2, 3] . The purposes of such blind prediction challenges are to test the state-of-the-art computational methodologies and protocols in the field of computer-aided drug design/ discovery (CADD), and advance the development of CADD technologies. The D3R Grand Challenge 3 (GC3) was held from August 31st 2017 to December 15th 2017 and involved five subchallenges: Subchallenge 1, Cathepsin S; Subchallenge 2, Kinase Selectivity; Subchallenge 3, Kinase Activity Cliff JAK2_SC3; Subchallenge 4, Kinase Activity Cliff TIE2; Subchallenge 5, Kinase Mutants [4] . Participants from the computational chemistry community worldwide were asked to complete the subchallenges in the order they were listed, i.e., to complete the Subchallenge 1 first if the time and resource were limited, then complete Subchallenge 2 if their time and resource were allowed, and so on. We only participated in the Subchallenge 1 (the Cathepsin S set) due to limited computing resource.
The cathepsins are a very important family of cysteine proteases in humans. They are in various functions, such as bulk intracellular proteolysis in the endolysosomal system, cell death and inflammation signaling in the cytoplasm,
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cell-cycle regulation in the nucleus, signaling in the extracellular environment, etc [5] [6] [7] [8] . They are involved in a wide range of diseases such as cancers, chronic inflammation, infections, cardiovascular, and bone-related diseases [5] [6] [7] [8] . Therefore, they have been investigated as drug targets for more than 2 decades by pharmaceutical companies and academic institutions. There are 11 sub-types of cathepsins: B, C, F, H, K, L, O, S, V, W, and X [5, 6] . Among these sub-types, the Cathepsin S (CatS) has drawn special attentions, and its unique roles in the following diseases have been heavily investigated: rheumatoid arthritis, atherosclerosis, bronchial asthma, psoriasis, wound healing, myasthenia gravis, cancer, etc [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
The data set of Subchallenge 1 of GC3 was composed of 141 CatS ligands, among which 24 ligands had the protein-ligand co-crystallized structures determined with resolution < 3.0 Å, and 136 ligands had their bio-assay data (IC 50 ) measured [4] . However, all of the 24 crystal structures were not revealed at the beginning of the challenge, and all of the binding affinity data were blinded during the whole challenge time. This subchallenge was split into in three stages. In Stage 1A (August 31st 2017 to October 3rd 2017), participants were invited to: (a) predict the crystallographic poses of 24 ligands (the binding pose set), (b) predict the affinity ranking of 136 ligands (the affinity ranking set), and (c) predict the absolute or relative binding affinities for a subset of 33 compounds (the free energy set). After Stage 1A was done, the pseudo-apo crystal structures of 24 complexes (with corresponding ligand coordinates removed) were released, and participants were invited to re-predict the binding poses of the 24 ligands in their own corresponding receptor structures (self-docking). No affinity calculations were involved in this stage called Stage 1B (October 9th, 2017-October 23rd, 2017). In the last stage, Stage 2 (October 24th, 2017-December 15th, 2017), full coordinates of the 24 protein-ligand co-crystal structures were released and participants were invited to re-calculate the binding affinities for the ranking set and free energy set, with or without usage of the 24 released crystal structures.
Our group participated in the three predictions in Stage 1A and two predictions in Stage 2, but did not participate in the self-docking Stage 1B. According to the evaluation results done by the GC3 organizers in terms of root-meansquared-deviations (RMSD) for pose predictions, correlations coefficients (Kendall's τ and Spearman's ρ) and rootmean-squared-errors (RMSE) for affinity predictions [19] , our performances were relatively well compared to most of the other participants.
In the next section, we provide a detailed description of the methods and protocols which we employed for the predictions of binding poses and affinities of CatS subchallenge in D3R GC3. Especially, we focus on a new model named the extended linear interaction energy (ELIE) method, which were developed during our participating time in GC3. Then we present the results of applying the ELIE method to the CatS subchallenge in GC3, and discuss the advantages, shortcomings and future research plans with respect to the ELIE method.
Computational methods

Theory background
It has become a consensus that many docking methods can successfully predict near-native binding poses (position, conformation and orientation) of drug-like molecules in macromolecular receptors, but the corresponding scoring functions have poor abilities of estimating the binding free energies [2, 3] , due to the usage of only static conformations of the receptor protein in prior docking procedures. On the other end, physics-based alchemical free energy calculation methods apply molecular dynamics (MD) or Monte Carlo (MC) simulations to sample the dynamic conformations of the receptor, the ligand and the complex in explicit solvent, and can accurately describe the flexibilities of receptor-ligand binding and the solution. The free energy perturbation (FEP) and thermodynamic integration (TI) are examples of such rigorous methods [20] [21] [22] [23] [24] [25] . For instance, the FEP+ protocol implemented by Schrodinger Inc. (USA) have become the de facto standard metric for industrial drug modeling practice [22] . However, FEP and TI need to run on a series of unphysical intermediate states along the pathways of alchemical changes. The slow convergence problem and extensive sampling needed make FEP/TI too computationally demanding to be routinely used in real drug design projects. Consequently, some approximate end-point methods such as linear interaction energy (LIE) [26] [27] [28] [29] , molecular mechanics (MM) combined with Poisson-Boltzmann (PB) or generalized Born (GB) and surface area (SA) continuum solvation (MM/PBSA or MM/GBSA), have been developed [30] [31] [32] 
, which refers to protein and solution in the PL state, and solution only in the L state. The scale factor α was originally set as 0.5 according to the linear-response approximation (LRA), and β was taken to be 0.18. Later α was treat as adjustable between 0.33 and 0.5, depending on the charge and number of hydrogen-bond (H-bond) donors of the ligand [26] [27] [28] [29] . In many later applications, different α and β values were adjusted and adopted to get better results. An optional constant γ can also be added to improve the estimations. The MM/PBSA and MM/GBSA methods calculate a free energy from:
where ΔE inter is the change of internal bonded MM energy from the bonds, angles and torsions/dihedrals, ΔE elec is the change of MM electrostatic energy, ΔE vdw is the change of MM van der Waals energy, ΔG solv_pl is the polar solvation free energy, ΔG solv_np is the nonpolar solvation free energy, T is the absolute temperature, and ΔS is the entropy change. ΔG solv_pl can be calculated by any continuum-solvation method such as PB or GB. ΔG solv _ np is obtained from a linear relation to the solvent-accessible surface area (SASA). The entropic contributions can be estimated from normalmode analysis on a set of conformational snapshots obtained from MD/MC simulations.
In principle the binding free energy in Eq. 2 should be computed from the differences in PL, P and L states. But in real application, a much more common approach is to simulate only PL complex state, whereas the P or L conformations are approximated by simply removing other particles and only keeping the protein or ligand coordinates, respectively. This approach not only require fewer simulations, but also leads to an exact cancellation of ΔE inter . Hence, The LIE approach only considers contributions from the electrostatic and van der Waals interaction energies, and scale them by fitted coefficients. The MM/PBSA method considers contributions not only from the electrostatic and van der Waals interaction energies but also from the polar and nonpolar contributions of solvation, but no scale factors are applied to these terms. Inspired by both the LIE and the MM/PBSA methods, we developed a new method to estimate the binding free energies of protein-ligand complexes, which we named as the ELIE method. In our ELIE approach, different scale coefficients are applied to each of energy terms in the MM/PBSA free energy equation (Eq. 3):
where c0, c1, c2, c3, c4 and c5 are scaling coefficients, which need to be adjusted by fitting calculated binding free
energies to measured values of ligands in the training set. Once optimum values are obtained for these scaling coefficients, they can be used to test sets to predict the binding free energies. The target receptor in the training set should be the same as in the test set.
Protein preparation
At the beginning of Stage 1A, D3R provided two crystal structures of pseudo-apo CatS, in which the originally bound ligands were removed. We conducted literature search and retrieved co-crystal structures for CatS from the RCSB Protein Data Bank [33] Among these holo proteins, 3IEJ is particularly interesting because its ligand has a tetrahydropyrido-pyrazole core which is similar to the ligands in the challenge set, and this crystal structure has a good resolution of 2.18 Å [10] . Therefore, we decided to use it as starting point for Glide docking and MD simulations. The choice was also validated by the fact that the Cα RMSDs between the two pseudo-apo CatS crystal structures provided by D3R and 3IEJ are very low (0.35 Å).
After D3R released all 24 crystal structures in the CatS challenge set at the end of Stage 1B, we aligned them to 3IEJ and measured the Cα RMSDs. All of the newly released crystal structures of CatS have very low Cα RMSDs compared to 3IEJ. The CatS-14 complex (structure code GABJ) has the largest Cα RMSD (0.39 Å). We took GABJ as another starting point and repeated the procedures of MD simulations and binding affinity calculations with the ELIE model.
Selected crystal structures, including 3IEJ from Protein Data Bank, CatS_SO4_structure_D3R_GC3.pdb provided by organizers at the beginning of Stage 1A, gabj-CatS.pdb provided by organizers after Stage 1B, were prepared using the Protein Preparation Wizard [34] in Maestro [35] . Missing hydrogen atoms were added. Missing side chains were filled using Prime [36] . All ionizable residues were assigned their protonation states using Epik [37] assuming a pH of 5.0, which was employed in the binding assay [18] . All crystallographic water and ions were removed. In order to avoid steric clashes, hydrogens of remaining protein (with or without ligand) structures were minimized using OPLS3 force field [38] while the heavy atoms were restrained using an RMSD cutoff of 0.3 Å.
Ligand preparation
For the CatS subchallenge in GC3, D3R organizers provided participants with SMILES strings of 141 ligands, among which 24 ligands (from CatS_1 to CatS_24) have co-crystal structures, and 136 ligands have measured IC 50 data between 1 3 3 and 8500 nM. These ligand molecules are referred as the challenge set in this article.
Most of the challenge set ligands share a common core scaffold of tetrahydropyrido-pyrazole, except for two ligands (CatS_4 and CatS_6) which have a pyridinone-like core ( Figure S1 in Support Information). Through literature search, we collected structure information of approximately 130 ligands which also have a tetrahydropyrido-pyrazole core scaffold and which have corresponding IC 50 data experimentally measured [9] [10] [11] [12] [13] . These ligand molecules are referred as the training set in this article.
The 3D structures of all ligands in both the training and challenge sets were constructed by manually modifying the native ligand of a crystal structure (PDB ID 3IEJ) [10] . Ligand protonation states were manually assigned. According to the reference [18] listed by the D3R organizer, the bio-assay measurements were performed at pH 5.0 [18] . Therefore, we protonated all nitrogen atoms which are not in or connected to a double bond or aromatic bond. As a consequence, all of the ligand molecules have +1 or +2 net charges. The ligands were geometrically optimized in vacuum by Maestro using OPLS3 force-field [38] . The stereochemistry in all ligands were visually inspected against the descriptions in the provided SMILES strings for the challenge set or in the literature for the training set [9] [10] [11] [12] [13] .
Pose prediction
Two docking approaches were used: Glide XP (extended precision) [39, 40] , and AutoDock Vina [41] .
For the Glide XP method, the prepared X-ray structure from PDB ID 3IEJ was selected as the receptor template, because its co-crystallized ligand has the same scaffold core as in most of the challenge set, and it has a very low Cα RMSD compared to the two pseudo-apo CatS crystal structures provided by D3R. Glide grid was generated with default options: van der Waals radius scaling factor 1.0, partial charge cutoff 0.25, centroid of workspace ligand, dock ligands similar in size to the workspace ligand, no constraints, no rotatable groups. The 3D ligand conformations as prepared above were used as the starting geometries. Each of the 24 ligands was docked against the same grid, using extra-precision (XP) sampling, reward intramolecular hydrogen bonds, post-docking minimization, and outputting a maximum of five poses per docking. All poses were ranked using Glide's XP docking scoring function. The best docking pose for each ligand was selected and submitted as our pose prediction.
The open source docking program Autodock Vina (version 1.1) was also employed. The CatS_SO4_structure_ D3R_GC3.pdb provided by organizers was used as the receptor template. To prepare the input structures for the docking, the 3D structures in mol2 format of the 136 ligands were generated by Maestro from their SMILES format with considering all possible protonation and chirality. The MGLTools 1.5.4 was used to prepare the PDBQT files for the receptor and ligands [42] . The dimensions of the docking rectangular box were 37 Å × 50 Å × 40 Å, to make sure the minimum distance between any atoms of the aligned ligands in the aforementioned 20 known co-crystallized CatS complexes to the box's walls is larger than 8 Å. The "exhaustiveness" of the global search was set 150 which is approximately 18 times larger than the default value 8, in order to increase the probability of finding the global minimum. Twenty binding modes were generated with random starting positions of each ligand, which had fully flexible torsion degrees of freedom. The maximum energy difference between the best and the worst binding modes was set 7.0 kcal/mol.
MD simulation
The Antechamber tool [43] integrated in AmberTools16 was utilized to generate topologies for use in MD. The protein-ligand complexes were all solvated in a cubic box with water extending at least 10 Å from the complexes. Each system was neutralized adding Na + /Cl − ions to a final concentration of 0.15 M. Disulfide bonds in CatS were specified.
Atom types and parameters for ligands were assigned by the General Amber force field (GAFF) [44] . The partial charges for ligands were derived using the AM1-BCC method [45] , which was developed to resemble the partial charges derived by the restrained electrostatic potential (RESP) method [46] to fit the HF/6-31G* electrostatic potential generated using the GAUSSIAN 16 software package [47] . The ff14SB force-field [48] was adopted for CatS. Water molecules were treated with TIP3P water model [49] .
The MD simulations were carried out using the PMEMD. mpi and PMEMD.cuda modules in the AMBER16 package [50] [51] [52] . A set of five steps of energy minimization were performed to remove possible steric crashes, first on water and ions, followed with the protein and ligand complex. The harmonic restraint force constants decreased from 20 to 10, 5, 1 and 0 kcal/mol/Å 2 , progressively. After the minimization stages, each system was gradually heated from 0 to 300 K and then the temperature was kept at 300 K. The time step of 1 fs was used for the heating and first part of equilibrium stage, then a 2 fs time step for the rest part of equilibrium and following production stages. The periodic boundary condition was employed to produce a constant temperature and pressure (NPT) ensemble. The pressure was controlled at 1 atm with a pressure relaxation time of 1 ps. The temperature was regulated using Langevin dynamics [53, 54] with a collision frequency of 5 ps −1 . The Particle Mesh Ewald (PME) method [55, 56] was adopted to handle the long-range electrostatics and a 10 Å cutoff was set to treat real-space interactions. All of the covalent bonds involving hydrogen atoms were constrained with the SHAKE algorithm [57] . The simulation time for each system was 10 ns. The first 5 ns was treated as equilibration and the last 5 ns was used for production run.
MM/PBSA and ELIE calculations
For each system, 50 snapshots evenly extracted from the last 5-ns trajectory were used to calculate the MM/PBSA energy contribution terms (ΔE elec , ΔE vdw, ΔG solv_pl, ΔG solv _ np, TΔS). The water molecules and ions were removed first. The Poisson Boltzmann calculations were performed with the Delphi program [58] . The calculations employed the Parse radii for all atoms, a grid spacing of 0.5 Å, a fill ration of 90%, and a probe radius of 1.4 Å. The value of the exterior dielectric constant was set to 80. The solute interior dielectric constant was set to 1. The nonpolar solvation energy was calculated with the SASA approach, following rescaling using the equation ΔG nonpol = γ*dSASA + β, where γ = 0.00542 kcal/mol/Å 2 and β = 0.92 kcal/mol. The NMode module in AMBER16 was applied to derive the entropy loss during protein-ligand binding. After MM/PBSA calculations, the energy contributions in Eq. 3 were extracted using in-house programs and scripts and fed to Eq. 4 for ELIE analysis. The training set from literature was used to fit the scaling coefficients in Eq. 4, and then the fitted coefficients were directly applied to the challenge set to predict the binding free energies. (24) . The data of median, mean and STD RMSDs were evaluated by the challenge organizers [61] 
Metrics for analysis
Several measures were used in the coefficient calibrations and posteriori analysis, including mean unsigned error (MUE), root-mean-square error (RMSE), predictive index (PI) [59, 60] and Pearson's r.
The experimental binding free energies were estimated from measured IC 50 data [3, 22] :
Results and discussion
Pose prediction
The performances of our pose predictions in GC3 are shown in Fig. 1 . The submitted prediction with the Glide protocol (submission ID rm4m2) is displayed in red color, and 3 submissions with the AutoDock Vina protocol are colored in blue. Figure 1 demonstrates that Glide yielded a much better result than AutoDock Vina. The mean over all pose RMSDs of 24 CatS ligands for our Glide prediction is 3.70 Å (Fig. 1a) and the median over all pose RMSDs is 2.84 Å. The mean and median RMSDs for the three predictions with the AutoDock Vina protocols are all approximately 11.0 Å.
The submission rm4m2 contains only one predicted pose for each ligand, and the pose RMSDs for individual ligands are presented in Fig. 2 in red squares. Most of the ligand compounds were docked reasonably well. As a summary Figure 3a shows the superposition of predicted pose of CatS-19 to its native pose, which has the lowest RMSD (1.09 Å) in submission rm4m2, and the predicted pose overlays with the native pose very well. Figure 3b shows CatS-5 which has the largest RMSD (9.89 Å) in rm4m2, and the predicted pose has a flipped orientation comparing to its native pose. CatS-5 is the only tetrahydropyrido-pyrazole co-crystallized ligand which does not have a bottom-arm substitution, as shown in Fig. S1 and S2 in the Supplementary Material. Among the high RMSD ligands, CatS-4 and CatS-6 are the only two which do not contain a tetrahydropyrido-pyrazole core but a pyridinone instead (Fig. S1) .
The RMSD results for one of the AutoDock Vina predictions (fibez) are also presented in Fig. 2 
Affinity prediction by docking scores
In Stage 1A, we adopted the scoring functions by Glide and AutoDock Vina to predict the affinity ranking of 136 CatS ligands. The performances of our submissions are shown in Fig. 4 . Our Glide prediction w83jw and one of the Vina prediction ppyff have comparable performances and both among the top submissions in terms of mean and median Kendall's τ and Spearman's ρ, whereas Glide obviously outperforms Vina in pose predictions aforementioned (Fig. 1) .
Affinity prediction by ELIE
Due to the limited time and computing resource, in Stage 1A we only managed to complete MD simulations for the training set ligands and the 33 ligands in the free energy set with 3IEJ structure as the starting conformation. We fitted the ELIE scale coefficients in Eq. 4 using the training set experimental data, and then applied the fitted coefficients to blindly estimate the binding free energies of these 33 ligands in free energy set. As demonstrated in Fig. 5 , our submission pcy3r is at the top place in terms of mean and median correlation coefficients among all submissions to free energy prediction in Stage 1A.
In Stage 2, we completed MD simulations for all 136 ligands in the Affinity Ranking Set with the 3IEJ protein structure and estimated their binding free energies with ELIE model. We also took the GABJ (complex of CatS-14) protein structure and conducted corresponding MD simulations for all the training set and challenge set and then did the same procedures of coefficient fitting and binding free energy prediction. Figure 6 shows the retrospective analysis for the intermediate and final results for our submission ju2xy for ranking prediction in Stage 2. Figure 6a , c present the MM/PBSA calculated binding free energies for all the training set ligands. Comparing to the experimental binding free energies, the MM/ PBSA result of 3IEJ series leads to MUE of 2.33 kcal/ mol, RMSE of 3.19 kcal/mol, PI of 0.38, Pearson's r of 0.29, and the MM/PBSA result of GABJ series leads to MUE of 3.37 kcal/mol, RMSE of 4.21 kcal/mol, PI of 0.27 and Pearson's r of 0.22. After applying ELIE method, the 3IEJ series (with coefficients c1 = 0.9, c2 = 1.2, c3 = 1.2, c4 = 1.0, c5 = 0.4) leads to MUE of 1.10 kcal/mol, RMSE of 1.32 kcal/mol, PI of 0.54 and Pearson's r of 0.54 (Fig. 6e) , and the GABJ series (with c1 = 1.1, c2 = 0.9, c3 = 1.1, c4 = 1.3, c5 = 0.3) leads to MUE of 0.95 kcal/mol, RMSE of 1.15 kcal/mol, PI of 0.60, and Pearson's r of 0.60 (Fig. 6g) . Taking an exponential average of ELIE results of The performances of our ELIE protocol for the ranking prediction and the free energy prediction in Stage 2 are displayed in Fig. S3 and S4 , respectively. The performances of our submissions (shown in red) are above average in terms of mean and median Kendall's τ and Spearman's ρ. Actually eight submissions (m6yb2, e4emg, nmwas, ouj30, fugpp, 3pj6r, e3r6j, pi5ne) which are better than or similar to our ju2xy in Fig. S3, and 11 submissions (66qqk, tw62k, jk3no,  uch2m, rjnyn, vc0p5, feofk, fizwc, 2e2e3, bcfd0, 47ka6 ) which are better than or similar to our 6xwau and wdgzp are from the same participant group with the same method.
Discussion
One common problem and task in real drug design projects is to pre-select which compounds to synthesize and further test with experimental assays which are expensive in terms of both time and cost. Computational methods are expected to be useful in the lead identification and lead optimization stages.
Docking methods have evolved from single rigid receptor conformation-rigid ligand docking to multiple flexible receptor conformations-flexible ligand docking. Even though the state-of-the-art docking protocols are adequate in predicting the correct poses, they are still weak at predicting binding affinities due to the limitations in the scoring functions and ability of sampling. At the same time, alchemical free energy methods like FEP/TI are too computationally demanding to be used routinely for high-throughput screening.
The ELIE method can fill the gap between docking methods and the alchemical free energy methods, so that a more reasonable multi-step workflow can be constructed: firstly docking methods are used to screening millions of compounds for a target and narrow down the number of Fig. 4 Performance of our ranking predictions in Stage 1A of GC3 Subchallenge 1. Our submission by Glide scoring is displayed in red, and our submissions by AutoDock Vina scoring are displayed in blue. The evaluation data were provided by the challenge organizers [62] compounds to thousands or tens of thousands, and then methods like ELIE can be employed to further narrow down the pool of candidates to hundreds or thousands, and then alchemical free energy methods like FEP/TI can kick in to further reduce the candidate quantities to hundreds or tens or even less, before sending to experimentalists. We do not expect the ELIE method to achieve the same accuracy as the rigorous alchemical free energy methods, but we believe that it can be utilized in both lead identification and optimization stages in drug design projects for its balance between efficiency and accuracy.
In D3R GC3 Subchallenge 1 the ELIE method achieved reasonable accuracy for predicting binding free energies comparable to alchemical free energy calculations. Since ELIE is a newly developed method and the participation of this blind challenge is its first application, we think there should exist significant room for further improvement in the future which we plan to explore.
(1) As aforementioned, MD simulations before ELIE analysis in this practice were started from manually generated initial conformations. In order to be suited for routine usage in real drug design projects, initial conformations can be automatically generated from best predicted binding poses by molecular docking. (2) For each tautomer/protonation states of each ligand, multiple MD simulations from different initial structures of both receptors and ligands can be carried out to sample more conformational space. And correspondingly, various average algorithms can be explored. (3) In this challenge, the ELIE coefficients were obtained by coarsely testing. Better fitting algorithms like regres- protein structure is either 3iej or gabj as indicated by the labels of a-h, and "combine" by the labels of i and j stands for taking averages from the results of 3iej and gabj series as described in the main text (6) Manual preparation and intervention should be reduced as much as possible and a fully automated pipeline from beginning to end should be set up. (7) The possibility of merging some of the five energy contribution terms in Eq. 4 can be explored. For example, the ΔE elec and ΔE vdw terms can be merged into one term ΔE MM and share the same coefficient, or the ΔE elec and dE solv_pl terms can be merged into one term ΔE polar and share one same coefficient, or the ΔE vdw and dE solv_np can be merged into one term ΔE nonpolar and share one coefficient. By these ways, the five energy contribution terms in Eq. 4 can be merged to four terms to reduce the efforts for coefficient fitting. (8) The possibility of adopting GBSA continuum solvent model instead of PBSA can be explored.
Conclusion
We developed and utilized the ELIE method when participating in the D3R GC3 in 2017. This is an end-point methodology for calculating binding free energies. It takes snapshots from regular MD simulations of a protein-ligand complex, and then calculates the various energy contributions just like regular MM/PBSA or MM/GBSA. Then we fit the scaling coefficient of energy terms using training set ligands for which the binding affinities were measured, and apply the derived coefficients directly to query ligands of the same receptor target. In principle the ELIE protocol can introduce more accuracy on predictions of protein-ligand binding affinities than simple molecular docking and scoring because MD simulations can imitate the dynamics of protein-ligand interaction in reality. At the same time, it requires much less computing resource and time compared to alchemical free energy calculations. We thank D3R for the opportunity to test the usefulness of ELIE in a blind challenge which is like a real drug discovery project. The promising performance achieved by ELIE for the CatS subchallenge in GC3 suggests that ELIE could be a good choice for both the lead identification and lead optimization in drug discovery. Our ELIE method is still in the developmental phase and potential improvements have been discussed in this article. We expect a more widespread use of ELIE in prospective drug discovery projects in industry and academia.
